Clinical trials: Skin Toxicity
Malignant Skin Neoplasm, Melanoma
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote…
- Trial name
- NCT06675643
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Breast Cancer, Radiation Toxicity
Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer
RATIONALE: Drugs, such as lovastatin, may protect normal cells from the side effects of radiation therapy. PURPOSE: This phase II trial is studying how well lovastatin works in reducing side effects after radiation therapy in…
- Trial name
- NCT00902668
- Testing
- lovastatin, questionnaire administration, adjuvant therapy
- Volunteers
- 3 people
- Sponsor
- Virginia Commonwealth University
Node-positive Breast Cancer
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving…
- Trial name
- SWIFT RT (NCT06559540)
- Testing
- Hypofractionated radiation, Ultra-hypofractionated breast/chest wall and regional nodal radiation
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Washington University School of Medicine
Cardiotoxicity, Heart Failure
Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
This is a pilot prospective cohort study, in adult female subjects 18-85 years old with a diagnosis of invasive breast cancer who are planned for anthracycline-inclusive chemotherapy and followed up for a time period of 6 months…
- Conditions
- Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy
- Trial name
- NCT03155802
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stony Brook University
Breast Cancer
TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort Study
Rationale: The number of breast cancer (BC) patients at risk for long-term radiation-induced health problems is increasing, as their outcome is improving due to intensified treatment regimens, such as new systemic approaches and…
- Trial name
- THORACES (NCT02471079)
- Testing
- Radiotherapy
- Where
- Netherlands
- Volunteers
- 706 people
- Sponsor
- University Medical Center Groningen
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.
- Conditions
- Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum, Sjogren Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT03839069
- Testing
- minor salivary gland transplantation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Peripheral Neuropathy
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
Aim of the work This study aims to evaluate the possible beneficial role of silymarin in attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated peripheral neuropathy and improving cognitive…
- Conditions
- Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities, Hepatic Toxicity
- Trial name
- NCT05595109
- Testing
- Silymarin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Toxicity, Drug, Progression, Disease
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy
To assess CDK4/6i toxicity and effect on PFS in the Egyptian population
- Trial name
- NCT06558084
- Testing
- CDK4/6 Inhibitor
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Ain Shams University
Breast Neoplasms, Cardiovascular Diseases
Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer
In Europe, breast cancer is by far the most common form of cancer diagnosed in women today, accounting for 29% of all cases. The 5-year survival rate is approximately 90%.
- Trial name
- NCT02541435
- Where
- 2 sites in Norway
- Volunteers
- 1,600 people
- Sponsor
- St. Olavs Hospital
Colorectal Cancer, Gastric Cancer (GC)
Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)
Hand-foot syndrome (HFS) is a frequent adverse effect of capecitabine, presenting with redness, swelling, pain, and peeling of the skin on the palms and soles.
- Conditions
- Colorectal Cancer, Gastric Cancer (GC), Capecitabine, Hand Foot Syndrome
- Trial name
- DICLO-HFS (NCT07177560)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 151 people
- Sponsor
- Gazi University
Breast Cancer After Breast Conserving Surgery Indicating Postoperative Radiotherapy With Boost
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer
Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies.
- Trial name
- NCT01948726
- Testing
- Hypofractionation with simultaneous integrated boost
- Where
- 19 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University Hospital Schleswig-Holstein
Breast Cancer, Prostate Cancer
Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients
The primary objective of this study is to evaluate the prediction of late toxicity by the radiation induced CD8 T-lymphocyte apoptosis
- Trial name
- NCT00893035
- Where
- France
- Volunteers
- 885 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer, Nail Toxicity
Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions
The study compares three strategies to prevent/minimise nail problems occuring in women, with breast cancer, undergoing Taxane chemotherapy.
- Trial name
- NCT02583204
- Testing
- Onicolife nail drops, Nail polish
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- NHS Greater Glasgow and Clyde
Stevens-Johnson Syndrome, Corneal Blindness
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on…
- Trial name
- NCT01256489
- Testing
- Infliximab
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Cardiac Toxicity, Antitumor Drugs
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction…
- Conditions
- Cardiac Toxicity, Antitumor Drugs, Breast Cancer
- Trial name
- NCT04962425
- Testing
- Trastuzumab
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003068
- Testing
- amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Breast Cancer, Chemotherapeutic Agent Toxicity
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
RATIONALE: Acetyl-L-carnitine may prevent or lessen neuropathy caused by chemotherapy. It is not yet known whether acetyl-L-carnitine is more effective than a placebo in preventing neuropathy caused by chemotherapy.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue, Neuropathy
- Trial name
- NCT00775645
- Testing
- acetyl-L-carnitine hydrochloride
- Where
- 295 sites in United States
- Volunteers
- 437 people
- Sponsor
- SWOG Cancer Research Network
Advanced Solid Tumor, Metastatic Breast Cancer
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination…
- Trial name
- NCT04872166
- Testing
- BTX-A51
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Edgewood Oncology Inc.
Breast Neoplasms
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
- Trial name
- ATOPE (NCT03787966)
- Testing
- ATOPE-B, ATOPE-I
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad de Granada